Compare

LivaNova/$LIVN

1D1W1M3M6MYTD1Y5YMAX

About LivaNova

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Ticker
$LIVN
Sector
Health
Primary listing
NASDAQ
Employees
3,300

LivaNova Metrics

BasicAdvanced
$5B
26.11
$3.50
0.92
-

What the Analysts think about LivaNova

Analyst ratings (Buy, Hold, Sell) for LivaNova stock.
Analyst projections of the future price of LivaNova stock.

Bulls say / Bears say

Third-quarter revenue grew 10% year on year, and LivaNova raised its 2026 revenue-growth and adjusted EPS forecasts. Growth in both major segments gives the upgraded outlook support. (LivaNova PLC)
Strong oxygenator demand is an opportunity, and the company has started production on a dedicated new line to expand supply. Essenz placements and upgrades also offer room to grow as the system remains a minority of its installed base. (LivaNova PLC, Investing.com)
LivaNova’s FDA-approved aura6000 sleep-apnoea device opens a new market opportunity, while new Category I procedure codes are expected to take effect in 2028. That could support patient access, although meaningful commercial growth is still ahead. (LivaNova PLC, LivaNova PLC)
The 3T heater-cooler litigation remains costly and uncertain: LivaNova recorded a further $34 million provision in the third quarter, taking the provision to $44.2 million, and said actual losses may differ from its estimate. (StockTitan)
The separate SNIA environmental case leaves a large liability overhang. LivaNova reported a roughly $385 million current liability in its June filing, while the appeal and potential settlement process remained unresolved. (SEC)
Cash generation is not accelerating as quickly as earnings: third-quarter adjusted free cash flow fell to $55.8 million from $62 million, while capital spending rose to $77 million for the first nine months from $49 million. Capacity expansion and other investment could continue to weigh on near-term cash flow. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.

LivaNova Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

LivaNova Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing LivaNova

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.